WO2007054317A1 - Determination de la valeur d'un parametre physiologique - Google Patents

Determination de la valeur d'un parametre physiologique Download PDF

Info

Publication number
WO2007054317A1
WO2007054317A1 PCT/EP2006/010765 EP2006010765W WO2007054317A1 WO 2007054317 A1 WO2007054317 A1 WO 2007054317A1 EP 2006010765 W EP2006010765 W EP 2006010765W WO 2007054317 A1 WO2007054317 A1 WO 2007054317A1
Authority
WO
WIPO (PCT)
Prior art keywords
unit
body fluid
fluid sample
value
physiological parameter
Prior art date
Application number
PCT/EP2006/010765
Other languages
English (en)
Inventor
Werner Regittnig
Lukas Schaupp
Original Assignee
Medizinische Universität Graz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universität Graz filed Critical Medizinische Universität Graz
Publication of WO2007054317A1 publication Critical patent/WO2007054317A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/150022—Source of blood for capillary blood or interstitial fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150229—Pumps for assisting the blood sampling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150236—Pistons, i.e. cylindrical bodies that sit inside the syringe barrel, typically with an air tight seal, and slide in the barrel to create a vacuum or to expel blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150358—Strips for collecting blood, e.g. absorbent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150381—Design of piercing elements
    • A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150381—Design of piercing elements
    • A61B5/150503—Single-ended needles
    • A61B5/150511—Details of construction of shaft
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
    • A61B5/15101—Details
    • A61B5/15103—Piercing procedure
    • A61B5/15105—Purely manual piercing, i.e. the user pierces the skin without the assistance of any driving means or driving devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/155—Devices specially adapted for continuous or multiple sampling, e.g. at predetermined intervals

Definitions

  • the invention relates to devices for determining a value of a physiological parameter.
  • the invention further relates to methods of determining a value of a physiological parameter.
  • the invention relates to a test unit apparatus for such a device or method.
  • people with type 1 diabetes have to administer insulin from external sources for survival.
  • People with type 2 diabetes are usually not dependent on exogenous insulin administration, but may require it for control of blood glucose levels if this is not achieved with diet alone or with oral hypoglycemic drugs (see Moller, DE “New drug targets for type 2 diabetes and the metabolic syndrome", Nature 414:821-827, 2001).
  • Administration of exogenous insulin by means of the subcutaneous route provides the basis of the current insulin therapy (see Owens, DR “New horizons- alternative routes for insulin therapy", Nat Rev Drug Discov 1 :529- 540, 2002).
  • insulin is administered in the form of a bolus subcutaneous injection.
  • insulin pump therapy see Owens, DR “New horizons- alternative routes for insulin therapy", Nat Rev Drug Discov 1 :529- 540, 2002; Lenhard, MJ, and Reeves, GD “Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy", Arch Intern Med 161 :2293-2300, 2001).
  • a blood glucose testing system widely used by diabetic patients consists of a test strip and a measuring instrument.
  • a test strip is manually removed from a separate storage container and the rear or contact end of the test strip is inserted into the test strip holder of the instrument. After pricking the finger with a lancet, the testing end of the test strip is placed into the blood that has accumulated on the patient's finger. Due to capillary action, the blood is drawn through a capillary channel to the reagent materials contained in the test strip. The reagent materials then chemically react with the glucose drawn into the test strip to cause a detectable signal. The test strip is then disposed of after use.
  • the measuring instrument is adapted to receive a magazine containing a multitude of single-use test strips.
  • the test strips are accommodated in slots or cavities of the magazine.
  • one of the test strips is mechanically removed from the magazine and positioned in the test strip holder with the testing end of the test strip projecting out from the instrument. When in this testing position, the testing end of test strip can be placed into the blood being analyzed. After the blood has been analyzed, the used test strip is ejected from the instrument.
  • ISF interstitial fluid
  • CGMS ,,MiniMed Continuous Glucose Monitoring System
  • This device consists of an enzyme-tipped catheter sensor that is inserted into the subcutaneous tissue and wired to a pager-sized glucose monitor worn externally (see Mastrototaro, JJ "The MiniMed continuous glucose monitoring system", Diabetes Technol Ther 2 (Suppl 1):S13-S18, 2000).
  • CGMS , MiniMed Continuous Glucose Monitoring System
  • ISF is extracted from peripheral tissues and then transported to a glucose sensor that is located outside the body.
  • This approach has been the basis of commercially available devices, which measure glucose from ISF that has been extracted either by means of a microdialysis catheter (see Maran, A, Crepaldi, C, Tiengo, A, Grassi, G, Vitali, E, Pagano, G, Bistoni, S, Calabrese, G, Santeusanio, F, Leonetti, F, Ribaudo, M, Di Mario, U, Annuzzi, G, Genovese, S, Riccardi, G, Previti, M, Cucinotta, G, Giorgino, F, Bellomo, A, Giorgino, R, Poscia, A and Varalli, M "Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis", Diabetes Care 25:347-352, 2002) or a process denoted as "reverse iontophoresis" (see Tamad
  • the latter device is worn on the wrist or arm, and samples ISF that is drawn through the skin into an electrolyte by applying an electric field between two electrodes placed on the skin (i.e., reversed iontophoresis).
  • the electrodes are coupled to the skin by the electrolyte.
  • Glucose can then be measured using a glucose sensor in contact with the electrolyte.
  • the ISF sampling methods that are utilized by these systems include microdialysis (see Schoemaker, M, Andreis, E, Roper, J, Kotulla, R, Lodwig, V, Obermaier, K, Stephan, P, Reuschling, W, Rutschmann, M, Schwaninger, R, Wittmann, U, Rinne, H, Kontetzer, H and Strohmeier, W "The SCGMl System: subcutaneous continuous glucose monitoring based on microdialysis technique", Diabetes Technol Ther 5:599-608, 2003) and open flow microperfusion (see Trajanoski, Z, Brunner, GA, Schaupp, L, Ellmerer, M, Wach, P, Pieber, TR,
  • the ISF sampling by these methods involves the insertion of a microperfusion or microdialysis catheter into the subcutaneous tissue and the continuous transport of an isotonic fluid through the catheters by means of a pumping system.
  • the catheters are typically constructed from two tubular cannulae where the smaller inner cannula is mounted concentrically within the bigger outer cannula.
  • the perfusion fluid enters the catheters via the inlet tubing, moves through the inner cannula to the tip of the probe, and streams back in the space between inner cannula and the outer cannula which in the case of microdialysis contains a dialysis membrane (see L ⁇ nnroth, P, Jansson, PA and Smith, U "A microdialysis method allowing characterization of intercellular water space in humans", Am J Physiol Endocrinol Metab 253:E228- E231, 1987; Ungerstedt, U "Microdialysis - principles and applications for studies in animals and man", J Intern Med 230:365-73, 1991), or in the case of microperfusion possesses laser-drilled wholes in its wall (see Schaupp, L, Ellmerer, M, Brunner, GA, Wutte, A, Sendlhofer, G, Trajanoski, Z, Skrabal, F, Pieber, TR and Wach, P "Direct access to interstitial fluid in adi
  • Diffusional exchange occurs between the perfusate and the interstitial fluid adjacent to the outer cannula as the perfusion medium passes by the perforations or the membrane of the outer cannula.
  • the medium then flows through the outlet tubing to a sensor flow chamber outside the body.
  • US 5,242,382 discloses continuous or periodic measurement of blood gas parameters and blood pressure by separating plasma from blood and then using that plasma to measure the blood parameters.
  • Plasma is separated from blood in vivo with a filter implanted within a blood vessel, and the separated plasma is removed to extracorporeal apparatus for analyzing blood gas parameters or measuring blood pressure.
  • the use of plasma is equivalent to the use of whole blood for measuring blood gas parameters as the gas parameters reside in the plasma, not in the separated blood cells which remain in the blood vessel.
  • US 3,918,910 discloses a system for detecting the particular constituent of a fluid which comprises a cassette for holding a plurality of chemical reaction-testing strips each provided with a plurality of carriers containing reagents; means for drawing out said chemical reaction-testing strips one after another from the cassette and bringing a test fluid filled in a container into contact with the respective reagent carriers of the strip, means for producing an electric signal corresponding to the degree of a chemical reaction between the test fluid and any of said reagent carriers, and means for printing out data denoting the degree of said chemical reaction.
  • EP 0,542,260 discloses a test strip automatic supply device having a cylindrical container provided with a slit which is formed in a side wall thereof so as to contain an elongate test strip, a container supporting table having, in an upper portion thereof, a semi-cylindrical concave surface provided with an opening which is formed in a middle portion of the concave surface so as to allow a test strip fitted in the slit of the container to fall through and be taken out, and a carrying stage which receives and transports a test strip falling from the slit. While the transporting stage is transporting a test strip, optical means finds whether the test strip is faced up or down. The device has such a function that side reversing mechanism flips it over during transportation if it is face down. An operator only has to put test strips in the container. The tests strips are automatically let out of the container one at a time.
  • WO 1996/39209 discloses a method and an apparatus for maximizing the total amount of blood processed during an apheresis procedure by optimizing the concentration of anticoagulant in a donor/patient and the associated extracorporeal tubing set is provided.
  • a simplified model of an anticoagulant accumulation in a donor/patient's body is used to calculate an optimal anticoagulant infusion rate profile to the donor/patient during a blood processing procedure.
  • a maximum acceptable anticoagulant concentration in the donor/patient acts as an upper limit on the rate at which anticoagulant may be infused to the donor/patient using the optimized infusion rate profile.
  • a minimum acceptable anticoagulant level acts as a lower limit in optimally controlling the anticoagulant concentration in the extracorporeal tubing set.
  • Both the maximum acceptable anticoagulant level in the donor/patient and the minimum acceptable anticoagulant level in the extracorporeal tubing set may be customized for a specific donor/patient thereby allowing the optimized infusion rate profile and the extracorporeal tubing set anticoagulant concentration to be customized for the specific patient.
  • a device for determining a present value of a physiological parameter over time a device for determining a value of a physiological parameter, a method of determining a present value of a physiological parameter over time, a method of determining a value of a physiological parameter, and a test unit apparatus according to the independent claims are provided.
  • a device for determining a present value of a physiological parameter over time comprising a body fluid extraction unit adapted to extract a body fluid sample from a body under investigation, a coupling unit adapted to bring the extracted body fluid sample in functional contact with one of a plurality of test units, each of the test units being indicative of the present value of the physiological parameter when brought in functional contact with the extracted body fluid sample, and an evaluation unit adapted to determine the present value of the physiological parameter based on an analysis of the one of the plurality of test units brought in functional contact with the extracted body fluid sample.
  • a device for determining a value of a physiological parameter comprising a body fluid extraction unit adapted to extract a body fluid sample from a body under investigation, a coupling unit adapted to bring the extracted body fluid sample in functional contact with a test unit being indicative of the value of the physiological parameter when brought in functional contact with the extracted body fluid sample, a marker sensing unit adapted to sense at least one value of at least one marker parameter of the extracted body fluid sample, and an evaluation unit adapted to determine the value of the physiological parameter based on an analysis of the test unit brought in functional contact with the extracted body fluid sample, wherein the evaluation unit is adapted to perform a calibration for the determination of the value of the physiological parameter based on the sensed at least one value of the at least one marker parameter.
  • a method of determining a present value of a physiological parameter over time comprising extracting, by means of a body fluid extraction unit, a body fluid sample from a body under investigation, bringing, by means of a coupling unit, the extracted body fluid sample in functional contact with one of a plurality of test units, each of the test units being indicative of the present value of the physiological parameter when brought in functional contact with the extracted body fluid sample, and determining, by means of an evaluation unit, the present value of the physiological parameter based on an analysis of the one of the plurality of test units brought in functional contact with the extracted body fluid sample.
  • a method of determining a value of a physiological parameter comprising extracting, by means of a body fluid extraction unit, a body fluid sample from a body under investigation, bringing, by means of a coupling unit, the extracted body fluid sample in functional contact with a test unit being indicative of the value of the physiological parameter when brought in functional contact with the extracted body fluid sample, sensing, by means of a marker sensing unit, at least one value of at least one marker parameter of the extracted body fluid sample, and determining, by means of an evaluation unit, the value of the physiological parameter based on an analysis of the test unit brought in functional contact with the extracted body fluid sample, and performing, by means of the evaluation unit, a calibration for the determination of the value of the physiological parameter based on the sensed at least one value of the at least one marker parameter.
  • a test unit apparatus for a device for determining a value of a physiological parameter for instance for use with a device having the above-mentioned features
  • the test unit apparatus comprising at least one test unit comprising a physiological parameter indicating portion and comprising a marker parameter indicating portion, wherein the physiological parameter indicating portion is indicative of a value of a physiological parameter when brought in functional contact with an extracted body fluid sample, and wherein the marker parameter indicating portion is indicative of at least one marker parameter of the extracted body fluid sample when brought in functional contact with the extracted body fluid sample.
  • a medical device in which a current value of a parameter related to a (human or animal) body under examination is determined or monitored over any desired interval of time.
  • the device may monitor the glucose level of a type 1 diabetes patient or of a type 2 diabetes patient over night, for instance regularly.
  • a body fluid sample for instance an interstitial fluid (ISF) sample
  • ISF interstitial fluid
  • the test units When the body fluid sample gets in contact with a particular one of the plurality of the test units, the test units may be characteristically modified (for example due to a chemical reaction between the body fluid sample and a reactive substance of the test unit), wherein the degree of modification may allow to derive the actual value of the physiological parameter (for instance a glucose concentration of the body fluid sample).
  • the characteristic modification of the test unit brought in fluid communication with the body fluid sample may be detected and analyzed by an evaluation unit which may compute the present value of the physiological parameter. Subsequently, such a measurement procedure may be repeated with another one of the (single-use) test units.
  • the different test units of the test unit array may be moved (for instance rotated) manually or automatically so that, at a particular instance of time, a particular one of the test units may be brought in contact with a particular one of body fluid samples in a coupling area.
  • a plurality of single-use (for instance disposable) sensor units the reliability and the stability of the physiological parameter monitoring system may be significantly improved as compared to an approach in which a single sensor is used for the measurement a plurality of times.
  • a medical device for determining a value of a physiological parameter in which a single (or more than one) test unit is characteristically modified in accordance with the value of the physiological parameter.
  • the same body fluid sample is, simultaneously or sequentially, investigated by means of a marker sensing unit which may sense another parameter, a so-called (endogenous) marker parameter, of the extracted body fluid sample.
  • the evaluation unit may then compute the value of the physiological parameter based on the information derived from the test unit after being brought in fluid communication with the body fluid sample, wherein the calculation of the current value of the physiological parameter is calibrated based on the detected value of the marker parameter.
  • the concentration of a physiological substance in the body fluid sample may differ from an in vivo concentration of the physiological substance in the human being or the animal from, for example due to undesired concentration or dilution effects.
  • one or more other characteristic marker parameters may be determined so that this information may be used to correct the estimated value of the physiological parameter.
  • a level of one or more endogenous markers for instance a concentration of ions like Sodium and/or Potassium
  • a mathematical correction of the value of the physiological parameter for instance the glucose concentration in interstitial fluid.
  • marker parameters it may be advantageous to use a marker having a concentration inside the body which is well known and sufficiently stable. Then, a comparison between the measured value and the expected value is a reliable measure for the parasitic concentration or dilution of both, marker and physiological substance, due to the experimental measurement process.
  • a minimally invasive glucose monitor may be provided that can reliably substitute for fingerstick measurements.
  • the device may be adapted for determining a glucose concentration, a cholesterol concentration, a lactate concentration, an oxygen concentration, an ion concentration, an amount of bacteria, an amount of virus, and a medicament concentration as the physiological parameter.
  • the physiological parameter may be a concentration of a physiologically active substance in the body or at a special position inside the body.
  • the physiological parameter may be any medically relevant parameter characterizing the body fluid and/or the state of the body from which the body fluid has been taken. Such information may be used to determine whether and to which amount it is necessary or not necessary to provide any medicament, perform any treatment, initiate any alarm, repeat measurement or control any parameter.
  • a patient suffering from diabetes may be the subject of the investigation, and the glucose concentration and/or an insulin concentration of such a person may be estimated.
  • the device may be adapted for determining the physiological parameter continuously (or quasi-continuously) over time.
  • the term "continuously" (or quasi-continuously) may particularly denote that no or only small intervals are between points of time in which the value of the physiological parameter is monitored.
  • a time dependence of the physiological parameter may be derived from the investigations.
  • the body fluid extraction unit may be adapted to extract the body fluid sample by microdialysis, microperfusion, ultrafiltration, a porous tissue contactor, reversed iontophoresis, suction technique using one or more microneedles, and transdermal extraction (for instance using ultrasound and/or osmotic extraction buffer).
  • An interstitial fluid sampling by microdialysis or microperfusion may involve the insertion of a microperfusion or microdialysis catheter into the subcutaneous tissue and the continuous transport of an isotonic fluid through the catheters by means of a pumping system.
  • the catheters may be constructed from two tubular cannula, wherein a smaller inner cannula is mounted concentrically within a bigger outer cannula.
  • the perfusion fluid may enter the catheters via an inlet tubing, move through an inner cannula to a tip of the probe, and may stream back in the space between inner cannula and the outer cannula which in the case of microdialysis may contain a dialysis membrane (see Lonnroth, P, Jansson, PA and Smith, U "A microdialysis method allowing characterization of intercellular water space in humans", Am J Physiol Endocrinol Metab 253:E228-E231, 1987; Ungerstedt, U "Microdialysis - principles and applications for studies in animals and man", J Intern Med 230:365-73, 1991), or in the case of microperfusion may possess laser-drilled wholes in its wall (see Schaupp, L, Ellmerer, M, Brunner, GA, Wutte, A, Sendlhofer, G, Trajanoski, Z, Skrabal, F, Pieber, TR and Wach, P "Direct access to interstitial fluid in a
  • Diffusional exchange may occur between the perfusate and the interstitial fluid adjacent to the outer cannula as the perfusion media passes by the perforations or the membrane of the outer cannula.
  • the medium may then flow through the outlet tubing to a sensor flow chamber outside the body.
  • transdermal extraction using ultrasound and/or osmotic extraction buffer is disclosed as such in Kost, J, Mitragotri, S, Gabbay, RA, Pishko, M and Langer, R "Transdermal monitoring of glucose and other analytes using ultrasound", Nat Med 6:347-350, 2000, and in Chuang, H, Taylor, E and Davison, TW "Clinical Evaluation of a continuous minimally invasive glucose flux sensor placed over ultrasonically permeated skin", Diabetes Technol Ther 6:21-30, 2004, to which explicit reference is made herewith with regard to examples as to how to perform transdermal extraction using ultrasound and/or osmotic extraction buffer in the context of the invention.
  • Such a device may be worn on the wrist or arm of a patient, and may sample interstitial fluid that is drawn through the skin and to an electrolyte by applying an electric field between two electrodes placed on the skin.
  • the electrodes may be coupled to the skin by the electrolyte.
  • Glucose or any other physiological parameter can then be measured using a glucose sensor in contact with the electrolyte.
  • the body fluid extraction unit may be adapted to extract the body fluid sample as at least one of the group consisting of interstitial fluid, blood, lymph, cerebrospinal fluid, urine and tissue.
  • interstitial fluid may, in the context of this application, particularly denote liquid located between the cells in tissue of the body.
  • interstitial fluid may also denote (fatty) fluid between cells in the epidermis being a basis for the barrier function of the skin.
  • Interstitial fluid may be a good choice for a sample to determine the glucose concentration of a patient (for instance suffering from diabetes) in a soft manner.
  • the device may comprise a multiple test unit device including the plurality of test units.
  • a multiple test unit device may be realized as a replaceable or substitutable device.
  • Such a multiple test unit device may be a disk-shaped magazine or a cylindrical magazine.
  • a magazine may be a flat circular disk or a cylindrical drum.
  • Test units (for instance test strips) may be accommodated in slots or cavities of such a magazine.
  • one of the test units may be positioned so as to contact a body fluid sample to be investigated. When in this testing position, the testing end of the test strip can be placed into the body fluid sample being analyzed. After the body fluid sample has been analyzed, the used test strip may be ejected from the instrument or may be stored in a waste container.
  • Such a multiple test unit device may be designed in a similar manner as disclosed in one of the documents US 6,475,436, US 5,510,266, US 5,660,791, US 5,489,414, US 5,720,924, US 5,863,800, US 5,798,031, and may be manufactured in accordance with a method as disclosed in US 2005/0125162 or US 5,407,554.
  • the multiple test unit device may be a rotatable magazine.
  • the rotation may be controlled by means of the evaluation unit.
  • Energy for the rotation may be provided by muscle force of a user or by an electric energy supply of the device, for instance a battery.
  • the plurality of test units may be test strips. Each of these test strips may have a particular portion which is foreseen to be brought in contact with the body fluid sample in order to initiate or promote a characteristic alteration of at least one property of this test strip region indicative of the current value of the physiological parameter to be monitored.
  • one or more further test strip regions may be provided, for instance for a measurement of another parameter of the body fluid.
  • the device may comprise a detection unit adapted for performing the analysis of the one of the plurality of test units brought in functional contact with the extracted body fluid sample.
  • a detection unit may be an optical detection unit, an electrical detection unit, and/or a chemical detection unit.
  • An optical detection unit may determine information concerning the physiological parameter as a consequence of a modification of at least one optical property of a test unit after being brought in contact with the body fluid sample. For instance, the colour, the reflectivity, the absorption or a fluorescence property of such a test strip may be altered in a characteristic manner in dependence of the value of the physiological parameter.
  • the detection may be performed in an electrical manner, for instance using an effect like a modification of an ohmic resistance, a conductivity, a capacity, a magnetic parameter or the like of the test strip.
  • a chemical detection may be based on the fact that a test unit, after being brought in contact with the body fluid sample, may have modified chemical or biochemical characteristics, for instance a modified pH value, a modified concentration of a chemical substance, or the like.
  • a test unit may comprise glucose oxidase as sensor-active substance.
  • glucose oxidase may be chemically modified so that an electrical voltage may be generated (which may be measured in the context of an electrochemical detection) and/or that a dye may be generated (which may be measured in the context of a photometric detection).
  • Reagent materials chemically react with the glucose brought in contact with the test strip to cause an electrical signal (so-called electrochemical measuring technique) or a color change (so-called colorimetric measuring technique) in the test strip. Subsequently, the electrical signal or the color change is evaluated by the measuring instrument.
  • the evaluation unit may be a microprocessor.
  • a microprocessor may be a central processing unit (CPU). It may be manufactured as an integrated circuit (for instance monolithically integrated in a semiconductor substrate) and can be manufactured, for instance, in silicon technology.
  • Such a microprocessor may have computational resources and may, for instance, have access to a memory device (for instance an EEPROM) for storing data.
  • a memory device for instance an EEPROM
  • Such an evaluation unit may further control the entire or a part of the functionality of the device and may receive control commands from a user interface.
  • the evaluation unit may initiate output of information to a user interface, for instance provide the result of the monitoring in a graphical manner (in real time or as a retrospective).
  • the microprocessor may generate outputable information indicative of the current glucose value of the body under investigation.
  • the device may comprise a body fluid transportation unit adapted to transport the extracted body fluid through at least a part of the device.
  • a body fluid transportation unit may be a micropump or a miniature pump.
  • the body fluid transportation unit may comprise a marker sensing unit adapted to sense at least one value of at least one marker parameter of the extracted body fluid sample.
  • a marker parameter may be an endogenous marker parameter.
  • endogenous marker may particularly denote a substance whose concentration is known and regulated in the body fluid sample, for instance in interstitial fluid.
  • the marker sensing unit may be adapted to sense an exogenous marker parameter of the extracted body fluid sample.
  • exogenous marker may particularly denote a substance which is introduced from external into a (for example human) body under investigation. Further, the term “exogenous marker” may particularly denote a substance which is not produced by the (for example human) body, but may be produced artificially or by another organism. Examples for such exogenous markers are mannitol or innulin. Mannitol is a sugar-like substance which is essentially not metabolized by the human body and thus remains in the body with an essentially constant concentration in different regions of the body for a significant time. Based on blood and interstitial fluid samples extracted from the human body, a measured concentration of mannitol can be used, in good approximation, as a measure for the recovery (or exchange efficiency) of the interstitial fluid sample.
  • Exemplary marker parameters are ion concentrations of the extracted body fluid sample, for instance of interstitial fluid, and particularly Na + or K + ion concentrations.
  • the marker sensing unit and the detection unit may be provided as separate devices or as a common device. Realizing both functionalities in one and the same unit may have the advantage that the device is small in size and cheap in manufacture. Providing both units as separate elements may allow for an individual optimization of the functionality of the marker sensing unit and of the detection unit.
  • the marker sensing unit may be adapted to provide the sensed at least one value of the at least one marker parameter to the evaluation unit.
  • the evaluation unit may be adapted to determine the present value of the physiological parameter based on an analysis of the one of the plurality of test units brought in functional contact with the extracted body fluid sample and based on an analysis of the sensed at least one value of the at least one marker parameter. Therefore, by considering both simultaneously, namely the estimated value of the physiological parameter and the derived value of the marker parameter, the reliability of the calculated physiological parameter may be improved. Thus, the significance of result data output by the device may be improved.
  • the marker sensing unit may be adapted to provide the sensed at least one value of the at least one marker parameter to the evaluation unit, which may then perform a calibration for the determination of the present value of the physiological parameter based on the sensed at least one value of the at least one marker parameter.
  • Each of the plurality of test units may comprise a physiological parameter indicating portion and may comprise a marker parameter indicating portion.
  • Such a test unit or array of test units may be used within the device according to exemplary embodiments of the invention, or in another context.
  • the device may comprise an energy supply unit adapted to supply at least a part of the device with energy.
  • an energy supply unit adapted to supply at least a part of the device with energy.
  • units like the evaluation unit, a memory device, a pump, an optical detection unit, or the like may require electrical energy which may be provided by such an energy supply unit.
  • the energy supply unit may be provided rechargeable or replaceable.
  • the energy supply unit may be a battery, a fuel cell,or a solar cell. Realizing the energy supply unit by a battery, a single use battery or a rechargeable accumulator may be used. When using a solar cell, no separate energy supply unit is required and light of the environment may be used as source of energy for operating the device.
  • the device may further comprise a waste collector unit adapted to collect body fluid sample after transportation through at least a part of the device.
  • a waste collector unit adapted to collect body fluid sample after transportation through at least a part of the device.
  • the device may further comprise a reservoir unit adapted to hold an injection fluid adapted to be injected into the body under investigation.
  • the device may also control injection, infusion or insertion of any material into the body under investigation, for instance buffers, test fluids, medications or the like.
  • the reservoir unit may be adapted to hold a glucose regulating substance (that is particularly any substance which may have an influence on the glucose level in an organism), like insulin, an insulin-like growth hormone, adrenaline or the like.
  • a glucose regulating substance that is particularly any substance which may have an influence on the glucose level in an organism
  • the reservoir unit may be adapted to hold a medication as the injection fluid. Therefore, as a consequence of the determination of the value of physiological parameter, the evaluation of the device may decide that it is necessary to inject a particular amount of medication into the patient's body. For instance, when it has been detected that the glucose level has become too high, insulin may be injected in the body of the person. For instance, when it has been detected that the glucose level has become too low, glucose may be injected in the body of the person.
  • the reservoir unit may be adapted to hold insulin as the injection fluid.
  • the reservoir unit may, additionally or alternatively, be adapted to hold aldosterone or bi-carbonate or any other physiologically active substance as the injection fluid.
  • the hormone aldosterone may be injected into a body under investigation, as a reaction to the determination of corresponding values of a physiological parameter like an ion concentration, for instance the Potassium concentration.
  • Aldosterone regulates the electrolyte and water concentrations in the human body. It increases resorption of Sodium ions from the kidney, thus increasing the Sodium level in the blood. Secretion of Potassium ions and water ions is promoted. Consequently, the Potassium level in the blood is reduced. Simultaneously, water is retained. Therefore, aldosterone also has an influence on the regulation of the blood volume and the blood pressure.
  • a physiological parameter and an assigned medication is the lactate or oxygen concentration in blood (as physiological parameter) and a bicarbonate infusion (as the medication).
  • the oxygen concentration may be reduced and the lactate concentration may be increased due to a less efficient glucose metabolism. If the presence of such a scenario is detected by measuring the lactate or oxygen concentration in blood as the physiological parameter, substances like bicarbonate or oxygen may be injected in order to locally improve blood circulation.
  • the evaluation unit may be adapted to control or regulate release of the injection fluid from the reservoir unit into the body under investigation.
  • the device may be an autarkic and automatic system which may measure a value of one or more physiological parameters and, as a consequence of such a measurement, may initiate injection of a certain amount of medication into a person's body. Therefore, the evaluation unit may be adapted to control or regulate release of the injection fluid from the reservoir unit into the body under investigation based on the determined present value of the physiological parameter.
  • test unit apparatus further exemplary embodiments of the test unit apparatus will be described. However, these embodiments also apply for the device for determining a value of a physiological parameter, for the device for determining a present value of a physiological parameter over time, for the method of determining a present value of a physiological parameter over time, and for the method of determining a value of a physiological parameter according to the independent claims.
  • the test unit apparatus may be adapted as a magazine comprising a plurality of the test units.
  • a magazine may be a disk-shaped magazine or a cylindrical magazine.
  • Such a magazine may be a flat circular disk or a cylindrical drum.
  • a multiple test strip device to sequentially measure the ISF glucose sampled continuously or intermittently by means of techniques such as microdialysis, microperfusion, ultrafiltration, porous tissue contactor, transdermal extraction, reversed iontophoresis, suction technique using microneedles, or transdermal extraction using ultrasound and/or osmotic extraction buffer.
  • techniques such as microdialysis, microperfusion, ultrafiltration, porous tissue contactor, transdermal extraction, reversed iontophoresis, suction technique using microneedles, or transdermal extraction using ultrasound and/or osmotic extraction buffer.
  • Endogenous markers may be defined as substances whose concentrations are known and tightly regulated in the ISF.
  • concentrations of the markers both in ISF and extracted fluid possible confounding influences of the extraction process on the fluid levels of the substances (e.g. concentration or dilution of the substances in the fluid) can be quantified and then used to compensate for influences of the extraction process on the glucose levels in the extracted fluid, thereby improving the estimation of the blood glucose concentrations from the glucose values obtained with the multiple test strip device
  • the sampling of interstitial fluid and determination of the glucose may be automated.
  • glucose determination can be performed with reduced discomfort.
  • Embodiments of the system may reliably substitute for f ⁇ ngerstick measurements in the treatment of diabetes.
  • Embodiments of the system may allow to detect early stages of blood glucose excursions in patients particularly with type 1 diabetes. This may be especially useful during periods of sleep.
  • Embodiments of the system may be combined with an insulin infusion pump to build a glucose-controlled insulin infusion device (i.e. an artificial pancreas) particularly for the treatment of type 1 diabetes.
  • a glucose-controlled insulin infusion device i.e. an artificial pancreas
  • a therapy system for patients suffering from diabetes is provided according to an exemplary embodiment.
  • a continuous glucose measurement may be provided, in which multiple (single-use) sensor strips may be employed so that the reliability and stability of the measurement may be improved as compared to a continuous glucose measurement with a single sensor.
  • a measurement of the physiological parameter for instance glucose
  • an extraction process for extracting the body fluid sample should modify the concentration of the glucose and the endogenous marker, such a distortion may be detected by analyzing the measured value of the endogenous marker(s) and the distortion can be removed or reduced by calculating a corrected value of the physiological parameter.
  • a glucometer which works on the basis of a measurement strip magazine.
  • a body fluid sample to be examined may be extracted by means of a catheter like instrument.
  • the glucose concentration may be measured quite frequently, for instance once or twice an hour, or every 10 seconds.
  • a patient suffering from diabetes may carry the device in a similar manner like a mobile phone or a wristwatch.
  • the device may alarm the patient and/or may initiate an increase or a decrease of the insulin level.
  • the body fluid sample (for example ISF) may be extracted from any desired part of the human body, for instance from the fatty tissue close to the belly, from the overarm, or from the femoral.
  • the glucose level of a patient treated in an intensive care unit may be controlled or regulated. It is believed that treating a patient in an intensive care unit with an increased glucose level may increase the probability that the patient survives.
  • Fig. 1 shows a device for determining a value of a physiological parameter according to an exemplary embodiment of the invention.
  • Fig. 2 shows a device for determining a value of a physiological parameter according to an exemplary embodiment of the invention.
  • Fig. 3 shows a device for determining a value of a physiological parameter according to an exemplary embodiment of the invention.
  • Fig. 4 shows a device for determining a value of a physiological parameter according to an exemplary embodiment of the invention.
  • Fig. 5 shows a test unit apparatus according to an exemplary embodiment of the invention.
  • Fig. 6 shows a diagram illustrating the time dependence of a glucose level measured in different scenarios.
  • a device 13 for determining a present value of glucose according to an exemplary embodiment of the invention will be described.
  • the device 13 comprises a body fluid extraction unit 2 adapted to extract body fluid from a region of an organism, particularly interstitial fluid from tissue 1 of a human patient.
  • the device 13 comprises a coupling unit 6 to bring the extracted body fluid, particularly interstitial fluid, in contact with one test strip 8 of a magazine 9 of test strips 8.
  • a colour of the test strip 8 is modified accordingly so as to be indicative of the value of the glucose concentration of the interstitial fluid.
  • an evaluation unit 10 which may also be denoted as a control unit is provided as a microprocessor which determines the actual value of the glucose concentration in the interstitial fluid or in the blood of the patient based on an analysis of the test unit 8 after being brought in functional contact with the interstitial fluid sample.
  • the evaluation unit 10 may initiate rotation of the magazine 9 after expiry of a certain time interval, for instance every five minutes. Thus, the value of the glucose may be determined again, thus intermittently over time.
  • the multiple test unit device 9 is, in the described embodiment, a cylindrical magazine which can be rotated under control of a user or under control of the microprocessor 10.
  • the coupling unit 6 comprises an optical detection unit for optically detecting a colour or a reflectivity of the test strip 8 after being brought in contact with the interstitial fluid. The detected information may then be supplied to the microprocessor 10.
  • a pump 4 pumps the extracted interstitial fluid through the device 13.
  • a marker sensing unit 5 senses the value of endogenous markers, like a Sodium ion concentration and/or a Potassium ion concentration.
  • the evaluation unit 10 is provided with the information determined by the marker sensing unit 5 and may then determine the value of the glucose concentration based on an analysis of the information from the optical detection device 6 in combination with the information provided by the marker sensing unit 5.
  • the process of evaluating the glucose concentration in the blood can be calibrated by means of the determined marker information.
  • a battery 12 is provided as an energy supply unit to supply several components of the device 13 with electrical energy.
  • a waste collector unit 11 collects interstitial fluid after being transported through the device 13.
  • the system 13 of Fig. 1 allows for an intermittent monitoring of glucose and for a continuous monitoring of endogenous markers.
  • Fig. 1 illustrates the system 13 in which the glucose in the extracted fluid is monitored with multiple single-use test strip elements 8, and the fluid levels of the endogenous markers are continuously monitored using continuous sensors 5.
  • ISF of a peripheral tissue 1 is transported from the ISF sampling unit 2 through an inlet conduit 3 to the endogenous marker sensing element 5, in which the sensing of the endogenous markers is performed continuously.
  • the ISF is guided to the coupling unit 6 in which the extracted ISF is sequentially brought into contact with the test strips 8 accommodated in the magazine 9.
  • the magazine 9 is rotatable so that the test strips 8 can be contacted individually.
  • the coupling unit 6 is also adapted for the optical evaluation of the color change occurring in the glucose sensing area 7 on the test strip 8 (and may be adapted, additionally or alternatively for electrically connecting test strip 8 with the microprocessor 10 so that the electrical signals produced in glucose sensing area 7 of the test strip 8 can be transferred to the microprocessor 10).
  • the microprocessor 10 also acquires signals from the endogenous marker sensing element 5. By using both the glucose and endogenous marker signals, the microprocessor 10 calculates blood glucose concentrations.
  • the ISF not drawn into the test strips 8 flows from the coupling unit 6 to the waste collector 1 1.
  • the battery 12 is provided for energy supply.In the following, referring to Fig. 2, a device 13 for determining a present value of glucose according to an exemplary embodiment of the invention will be described.
  • FIG. 2 shows the system 13 in which both glucose and endogenous marker(s) in the extracted fluid are monitored with multiple single-use test strip elements 8.
  • each of the test strips 8 has not only a sensing area for glucose 7 but also sensing areas for the endogenous markers 5.
  • the fluid drawn into capillary of the single-use test strips 8 is analyzed concurrently for glucose and endogenous markers.
  • the ISF not drawn into the test strips 8 flows from the coupling unit 6 to the waste collector 11.
  • This embodiment allows for glucose sensing with multiple single-use test elements in the ISF extracted by means of Porous Tissue Contactors (PTC).
  • PTC Porous Tissue Contactors
  • Fig. 3 illustrates an embodiment of the system 13 comprising a PTC 2 inserted into the subcutaneous tissue 1, two connecting tubes 3, 15, a miniature pump 4, a coupling unit 6, a rotatable magazine 9 housing single-use test elements 8, a microprocessor 10, a battery 12, and a reservoir 19 with two fluid chambers 1 1, 14 separated by movable septa 20.
  • An isotonic, ion- and glucose- free perfusate from the fluid chamber 14 is pumped through the inlet tubing 15 into the longitudinal bore 16 of the non-porous soft cannula 18 up to its distal end.
  • the fluid emerged at the distal end of the non- porous soft cannula 18 is then forced to flow into the porous layer 17 on top of the impervious cannula wall 18.
  • the medium After emerging at the proximal end of the porous layer, the medium then flows through the outlet tube 13 into the coupling unit 6.
  • the coupling unit 6 the medium is sequentially brought into contact with the test strips 8 which contain sensing elements for glucose 7 and conductivity 5.
  • the medium drawn into the capillary of the single-use test strips 8 is then analyzed concurrently for glucose and conductivity.
  • the microprocessor 10 acquires the glucose and conductivity data from the coupling unit 6 and converts them into blood glucose readings.
  • the ISF not drawn into the test strips 8 flows from the coupling unit 6 to the waste fluid chamber 11.
  • ions are used as endogenous markers.
  • the exchange efficiency during the sampling process of an ion can be estimated as the ratio of the ion concentration in the PTC effluent to the ion concentration in the plasma.
  • the exchange efficiency of ions like Na + and K +
  • the glucose concentration in the ISF can be estimated as the glucose concentration in the PTC effluent divided by the ionic exchange efficiency.
  • the ionic exchange efficiency itself can be easily monitored by applying the electrical conductivity measurement. This is possible, because the electrical conductivity equals the weighted sum of all ionic concentrations in a fluid.
  • Fig. 4 illustrates glucose monitoring and glucose- controlled insulin infusion.
  • Fig. 4 illustrates another exemplary embodiment of the system 13.
  • the glucose monitoring with multiple single-use test strip elements is coupled with glucose-controlled insulin infusion means.
  • the system comprises the PTC 2 inserted into the subcutaneous tissue 1, two connecting tubes 3, 15, two miniature pumps 4, 4 ' , a coupling unit 6, a rotatable magazine 9 housing single-use test elements 8, a microprocessor 10, a battery 12, and a reservoir 19 with two fluid chambers 11, 14 one filled with a perfusate fluid containing insulin 21 at a high concentration (e.g., 100 U/ml).
  • a high concentration e.g. 100 U/ml
  • Pump 4 transports the perfusate fluid from the perfusate chamber 14 via the inlet tubing 15 into the PTC 2, and pump 4' sucks the ISF from the PTC through the outlet tubing 3 to the coupling unit 6, in which the ISF is sequentially brought into contact with the test strips 8, which contain sensing elements for glucose 7 and conductivity 5.
  • the ISF drawn into the capillary of the single-use test strips 8 is then analyzed concurrently for glucose and conductivity.
  • the microprocessor 10 acquires the glucose and conductivity data from the coupling unit 6 and converts them into blood glucose readings. Based on the blood glucose readings, the microprocessor 10 calculates the appropriate insulin delivery rate.
  • the insulin delivery rate is adjusted by altering the flow rate of pump 4 (e.g., between 0.5 and 7.0 microl/min).
  • the flow rate of pump 4' may be similar or lower than that of pump 4 (e.g., 0.5 microl/min). Also, pump 4' may operate discontinuously. Again, the ISF not drawn into the test strips 8 flows from the coupling unit 6 to the waste fluid chamber 11.
  • test unit apparatus 9 according to an exemplary embodiment of the invention will be explained.
  • test unit apparatus may be implemented as the magazine 9 of any one of the devices 13 as illustrated in Fig. 1 to Fig. 4.
  • the test unit apparatus 9 for the device 13 for determining a value of a physiological parameter comprises a plurality of test units 8 as circumferential teeth of a rotatable disk-shaped substrate 50.
  • Each of the test units 8 comprises a physiological parameter indicating portion 51 and comprises a marker parameter indicating portion 52.
  • the physiological parameter indicating portion 51 is indicative of a value of a physiological parameter - like a glucose concentration - when brought in functional contact with an extracted body fluid sample - like an interstitial fluid sample.
  • the marker parameter indicating portion 52 is indicative of one or more marker parameters - like an ion concentration - of the extracted body fluid sample when brought in functional contact with the extracted body fluid sample.
  • Fig. 6 shows a diagram illustrating the time (plotted along the abscissa of the diagram) dependence of a glucose level (plotted along the ordinate of the diagram) measured in different scenarios.
  • Fig. 6 illustrates the time course of (blood) plasma glucose
  • the concentrations of glucose in plasma 62 were determined using a glucose oxidase method (Cobas Mira; Roche Diagnostics, Rotnch, Switzerland) and the glucose concentrations in the effluents of the PTC 60 were measured using a multiple test strip device (Accu-Chek Compact plus; Roche Diagnostics, Mannheim, Germany).
  • the conductivity in the plasma and the PTC effluent samples were determined using a contactless conductivity detector (TraceDec, I: S. T, Strasshof, Austria).
  • the ISF glucose concentration 61 was calculated as the glucose concentration in the effluent 60 divided by the ratio of the measured conductivity in the probe effluents and the conductivity in plasma.
  • the glucose concentration in the blood plasma of the piglet was about 80 mg/dl. Due to the start of the intravenous endotoxin infusion after the baseline period of 60 min, the glucose concentrations in plasma decreased to a nadir of 35 mg/dl at 120 min. The plasma glucose concentration increased slowly thereafter and by the end of the experiment at 240 min the plasma glucose concentration was 45 mg/dl.
  • the glucose concentration time course in the ISF around the PTC 61 was similar to that observed in plasma 62.
  • An aim of the study in the context of Fig. 6 was to employ a porous tissue contactor for ISF sampling from subcutaneous adipose tissue and to examine whether a stable relationship between the blood glucose concentration and the glucose concentration in the sampled ISF exists when this porous tissue contactor is simultaneously used to deliver insulin to this tissue.
  • porous tissue contactors were fabricated from a porous polyethylene (PE) sheet of hydrophilic type (sheet thickness: 0.6 mm, Average Pore Size: 7-16 ⁇ m; Porex Technologies Corporation, Fairburn, GA, USA), a porous PE sheet of hydrophobic type (sheet thickness: 0.6 mm, Average Pore Size: 40-100 ⁇ m;
  • PE polyethylene
  • PTFE tubing OD: 1.0 mm, ID: 0.5 mm; Bohlender GmbH, Gr ⁇ nsfeld, D), and syringe needles (0.5 x 25 mm, 21- gauge; BD Microlance, Becton Dickinson, Fraga).
  • a porous stripe was slid into the cut-out portions of the PTFE tube and the end portions of the porous stripe ( ⁇ 5mm) were then press fit into the PTFE tube portions adjacent to the cut-out portions. Finely, for making the connections to a Tygon tubing, the tips and hubs of syringe needles were cut off by use of a small triangle file, and the excised needle shafts were then pushed into the ends of the PTFE tubes.
  • a piglet aged 3 months and weighing -30 kg was fasted overnight with free access to water.
  • the piglet was anesthetized by intramuscular injection of ketamine and pentobarbital sodium.
  • the piglet was placed in supine position on a heating blanket and intubated orotrachealy. Thereafter, mechanical ventilation was started and respirator settings were adjusted to maintain blood gas values within the physiologic range. Anesthesia was maintained by adding halothane to the inspiratory gas mixture.
  • a catheter was placed in the right carotid artery to allow blood withdrawal during the experiment and another catheter was inserted into the right femoral vein to be used for all study infusions.
  • a third catheter was placed suprapubically into the bladder.
  • halothane inhalation was stopped and anesthesia was subsequently maintained by intravenous infusion of piritramide and pancuroniumbromide.
  • the piglet received an intravenous infusion of an endotoxin ⁇ Escherichia coli lipopolysaccharide). The piglet was monitored thereafter for 4 hours and then killed with an intravenous bolus injection of KCl.
  • a hydrophilic and a hydrophobic PTC was placed into the abdominal subcutaneous adipose tissue of the piglet.
  • a 16-gauge catheter with an insertion needle fitted coaxially within the catheter (BD Angiocath; Becton-Dickinson, Sandy, Utah) was used to facilitate the placement of the PTCs.
  • the 16-gauge catheter and the needle were inserted through the skin, and advanced under the skin until ⁇ 60 mm of the proximal catheter portion was placed under the skin. The proximal end portion of the catheter and needle were then brought out through the skin. After carrying out this tunneling procedure, the insertion needle was withdrawn and the PTC was inserted into the 16-gauge catheter. The full length of the porous part of the PTC was then positioned in the tissue by holding the PTC on one end and withdrawing the 16-gauge catheter from the tissue at the same time.
  • Tygon tubes were used to connect the inlet and outlet of each PTC with a perfusate reservoir and a sample vial, respectively.
  • the Tygon tubes of each PTC were then inserted into a peristaltic pump, which continuously pumped perfusate fluid from the reservoir via the inlet tubing to the PTC, and sucked ISF from the PTC through the outlet tubing to the sampling vial.
  • the PTCs were perfused with an isotonic, ion-free perfusate solution containing insulin at a concentration of 1 U/ml.
  • Both PTCs were perfused with a high perfusion rate during the first 160 min of the experiment (-1.3 ⁇ l/min), and with a lower perfusion rate (-0.5 ⁇ l/min) during the last 90 min of the experiments.
  • the perfusate solutions was made up before the experiment by mixing an ion-free, isotonic mannitol solution (275 mM; Fresenius Kabi, Graz, Austria) with appropriate amounts of bovine albumin (10 g/1; Sigma Aldrich, Vienna, Austria) and human insulin (1 U/ml; Actrapid, Novo Industries, Copenhagen, Denmark).
  • Effluent samples from the PTCs were collected continuously in 30-min fractions, and arterialized blood samples were taken every 30 min.
  • the concentrations of glucose were determined in the plasma and effluent samples using a glucose oxidase method (Cobas Mira; Roche Diagnostics, Rotnch, Switzerland).
  • the conductivity in the plasma and the PTC effluent samples were determined using a contactless conductivity detector (TraceDec, I:S.T, Strasshof, Austria).
  • the ISF glucose concentration was calculated as the glucose concentration in the effluent divided by the extent of the mixing between perfusate and ISF (also called recovery).
  • the recovery in the PTC effluents was determined by applying the ionic reference technique.
  • the extent of the mixing between perfusate and ISF is calculated as the ratio of the measured conductivity in the probe effluents and the conductivity in plasma. This is possible, because the conductivity in the plasma is tightly regulated and is very close to the conductivity in the ISF.
  • GE is the measured effluent glucose concentration
  • SR is the recovery
  • CE and CP are the conductivity values in effluent and plasma samples, respectively. Because each probe effluent sample was collected over a specified time interval, the derived interstitial glucose values was considered valid at the midpoint of the interval.

Abstract

L'invention concerne un dispositif (13) qui détermine une valeur instantanée d'un paramètre physiologique au fil du temps, le dispositif (13) comprenant une unité d'extraction (2) de fluide corporel conçue pour extraire un échantillon de fluide corporel du corps étudié (1), une unité de couplage (6) conçue pour amener l'échantillon extrait de fluide corporel en contact fonctionnel avec une parmi plusieurs unités de test (8), chacune des unités de test (8) indiquant la valeur instantanée d'un paramètre physiologique lorsqu'elle est mise en contact fonctionnel avec l'échantillon extrait de fluide corporel, et une unité d'évaluation (10) conçue pour déterminer la valeur instantanée du paramètre physiologique à partir d'une analyse de l'unité sélectionnée de test (8) mise en contact fonctionnel avec l'échantillon extrait de fluide corporel.
PCT/EP2006/010765 2005-11-09 2006-11-09 Determination de la valeur d'un parametre physiologique WO2007054317A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73494505P 2005-11-09 2005-11-09
EP05024417 2005-11-09
EP05024417 2005-11-09
US60/734,945 2005-11-09

Publications (1)

Publication Number Publication Date
WO2007054317A1 true WO2007054317A1 (fr) 2007-05-18

Family

ID=37711073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/010765 WO2007054317A1 (fr) 2005-11-09 2006-11-09 Determination de la valeur d'un parametre physiologique

Country Status (1)

Country Link
WO (1) WO2007054317A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1954190A2 (fr) * 2005-11-15 2008-08-13 Luminous Medical, Inc. Determination d analytes sanguins
WO2010063290A2 (fr) 2008-12-05 2010-06-10 Fluisense Aps Dispositif de prélèvement de liquide organique et procédé correspondant
US10842427B2 (en) 2005-09-30 2020-11-24 Intuity Medical, Inc. Body fluid sampling arrangements
US11002743B2 (en) 2009-11-30 2021-05-11 Intuity Medical, Inc. Calibration material delivery devices and methods
US11045125B2 (en) 2008-05-30 2021-06-29 Intuity Medical, Inc. Body fluid sampling device-sampling site interface
US11051734B2 (en) 2011-08-03 2021-07-06 Intuity Medical, Inc. Devices and methods for body fluid sampling and analysis
US11399744B2 (en) 2008-06-06 2022-08-02 Intuity Medical, Inc. Detection meter and mode of operation
US11419532B2 (en) 2005-06-13 2022-08-23 Intuity Medical, Inc. Analyte detection devices and methods with hematocrit/volume correction and feedback control

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153900A1 (en) * 2002-02-08 2003-08-14 Sarnoff Corporation Autonomous, ambulatory analyte monitor or drug delivery device
WO2005001418A2 (fr) * 2003-05-30 2005-01-06 Pelikan Technologies, Inc. Procede et appareil pour l'echantillonnage de liquide organique et la detection d'analyte

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153900A1 (en) * 2002-02-08 2003-08-14 Sarnoff Corporation Autonomous, ambulatory analyte monitor or drug delivery device
WO2005001418A2 (fr) * 2003-05-30 2005-01-06 Pelikan Technologies, Inc. Procede et appareil pour l'echantillonnage de liquide organique et la detection d'analyte

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419532B2 (en) 2005-06-13 2022-08-23 Intuity Medical, Inc. Analyte detection devices and methods with hematocrit/volume correction and feedback control
US10842427B2 (en) 2005-09-30 2020-11-24 Intuity Medical, Inc. Body fluid sampling arrangements
EP1954190A4 (fr) * 2005-11-15 2010-10-13 Luminous Medical Inc Determination d analytes sanguins
EP1954190A2 (fr) * 2005-11-15 2008-08-13 Luminous Medical, Inc. Determination d analytes sanguins
US11045125B2 (en) 2008-05-30 2021-06-29 Intuity Medical, Inc. Body fluid sampling device-sampling site interface
US11399744B2 (en) 2008-06-06 2022-08-02 Intuity Medical, Inc. Detection meter and mode of operation
WO2010063290A2 (fr) 2008-12-05 2010-06-10 Fluisense Aps Dispositif de prélèvement de liquide organique et procédé correspondant
WO2010063290A3 (fr) * 2008-12-05 2010-07-22 Fluisense Aps Dispositif de prélèvement de liquide organique et procédé correspondant
US10286149B2 (en) 2008-12-05 2019-05-14 Fluisense Aps Body fluid sampling device and a method thereof
US11002743B2 (en) 2009-11-30 2021-05-11 Intuity Medical, Inc. Calibration material delivery devices and methods
US11933789B2 (en) 2009-11-30 2024-03-19 Intuity Medical, Inc. Calibration material delivery devices and methods
US11382544B2 (en) 2011-08-03 2022-07-12 Intuity Medical, Inc. Devices and methods for body fluid sampling and analysis
US11051734B2 (en) 2011-08-03 2021-07-06 Intuity Medical, Inc. Devices and methods for body fluid sampling and analysis
US11672452B2 (en) 2011-08-03 2023-06-13 Intuity Medical, Inc. Devices and methods for body fluid sampling and analysis

Similar Documents

Publication Publication Date Title
US20090312622A1 (en) Device And Method For Determining A Value Of A Physiological Parameter Of A Body Fluid
US8303533B2 (en) Device and method for delivery of a physiologically active substance depending on a measured physiological parameter
US5002054A (en) Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body
JP2686272B2 (ja) 毛細血管からの血漿限外濾過液を濾過し捕集するための装置
US20050137471A1 (en) Continuous glucose monitoring device
US4854322A (en) Capillary filtration and collection device for long-term monitoring of blood constituents
US6459917B1 (en) Apparatus for access to interstitial fluid, blood, or blood plasma components
US6537243B1 (en) Device and method for obtaining interstitial fluid from a patient for diagnostic tests
US5951521A (en) Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site
US6368274B1 (en) Reusable analyte sensor site and method of using the same
WO2007054317A1 (fr) Determination de la valeur d'un parametre physiologique
US20120123230A1 (en) Analyte monitoring systems and methods of use
JP5624322B2 (ja) 生体内電気化学的分析対象物感知を伴った液体供給
US20070191702A1 (en) Systems and methods for sensing analyte and dispensing therapeutic fluid
JP2008545460A (ja) 一体的な薬剤送達及び被分析物センサ器具
WO2009049823A1 (fr) Cathéter et procédés pour l'utiliser et le fabriquer
EP1359841A1 (fr) Systeme permettant de controler la concentration d'analytes dans des fluides corporels
US20100016831A1 (en) Catheter Having an Oblong Slit
JP2011507556A5 (fr)
EP0886488A1 (fr) Amelioration du transport transdermique de fluide par application de depression
JP2017118911A (ja) センサー基板、分析素子、グルコース測定装置およびインスリン供給装置
Tschaikner et al. Development of a single-site device for conjoined glucose sensing and insulin delivery in type-1 diabetes patients
US20080234563A1 (en) Device for and Method of Delivery and Removal of Substances in and From a Tissue or Vessel
Ricci et al. Ex vivo continuous glucose monitoring with microdialysis technique: The example of GlucoDay
WO2006076930A1 (fr) Dispositif de surveillance en continu du glucose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06828990

Country of ref document: EP

Kind code of ref document: A1